Table 2.
Serotypes of S. pneumoniae isolates producing biofilm, isolated alone or with H. influenzae
| S. pneumoniae | H. influenzae | Biofilm production by either S. pneumoniae or H. influenzae isolated together | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Biofilm production by S. pneumoniae Total | Biofilm production by S. pneumoniae isolated alone | Biofilm production by S. pneumoniae isolated with H. influenzae | Biofilm production by H. influenzae isolated with S. pneumoniae | ||||||
| S. pneumoniae Total | S. pneumoniae Biofilm+ | S. pneumoniae Biofilm - | |||||||
| Serotype (n) | n (%) | n (%) | Biofilm + n (%) | Hi Biofilm + | Hi Biofilm - | Hi Biofilm + | Hi Biofilm - | n (%) | n (%) |
| PCV7 | |||||||||
| 6B (11) | 10 (91) | 7/8 (88) | 3/3 (100) | 1 | 2 | 1/3(33) | 3/3 (100) | ||
| 9 V (2) | 2 (100) | 1/1 (100) | 1/1 (100) | 1 | 1/1 (100) | 1/1 (100) | |||
| 14 (10) | 6(60) | 1/2 (50) | 5/8 (63) | 5 | 3 | 8/8 (100) | 8/8 (100) | ||
| 18C (1) | 1 (100) | 0 | 1/1 (100) | 1 | 1/1 (100) | 1/1 (100) | |||
| 19F (17) | 7 (41) | 2/6 (33) | 5/11 (45) | 4 | 1 | 4 | 2 | 8/11 (73) | 9/11 (82) |
| 23F (13) | 5 (38) | 3 /7(43) | 2/5 (40) | 1 | 1 | 2 | 1 | 3/5 (60) | 4/5 (80) |
| Total | 31/54 (57.4) | 14/24 (58.3) | 17/29 (58.6) | 13 | 4 | 9 | 3 | 22/29 (75.9) | 26/29 (89.9) |
| PCV13 additional serotypes | |||||||||
| 1 (1) | 0 | 0 | 0/1 | 1 | 1/1 (100) | 1/1(100) | |||
| 3 (1) | 0 | 0/1 | 0/0 | 0 | 0 | ||||
| 5 (1) | 1 (100) | 0 | 1/1 (100) | 1 | 0/1 | 1/1 (100) | |||
| 6A (6) | 3 (50) | 2/5 (40) | 1/1 (100) | 1 | 1/1(100) | 1/1 (100) | |||
| 7F (2) | 2 (100) | 1/1 (100) | 1/1 (100) | 1 | 1/1(100) | 1/1 (100) | |||
| 19A (17) | 16 (94) | 8/8 (100) | 8/9 (89) | 6 | 2 | 1 | 7/9 (78) | 9/9 (100) | |
| Total | 22/28 (78.5) | 11/15 (73.3) | 11/13(84) | 8 | 3 | 2 | 10/13 (77) | 13/13 (100) | |
| Other serotypes | |||||||||
| 15B/C (15) | 14 (93) | 8/8 (100) | 6/7 (86) | 4 | 2 | 1 | 4/7 (57) | 6/7 (86) | |
| 15A (12) | 6 (50) | 3/5 (60) | 3/7 (43) | 3 | 4 | 7/7 (100) | 7/7 (100) | ||
| 11A (9) | 6 (67) | 3/3 (100) | 3/6 (50) | 3 | 2 | 1 | 5/6 (83) | 5/6 (83) | |
| 23B (9) | 3 (33) | 0/4 | 3/5 (60) | 3 | 2 | 5/5 (100) | 5/5 (100) | ||
| 23A (12) | 8 (67) | 6/8 (75) | 2/4 (50) | 1 | 1 | 2 | 2/3 (67) | 4/4 (100) | |
| 10A (6) | 3 (50) | 0/2 | 3/4 (75) | 1 | 2 | 1 | 2/3 (67) | 4/4 (100) | |
| 21 (5) | 2 (40) | 1/2 (50) | 1/3 (33) | 1 | 2 | 2/3(67) | 3/3 (100) | ||
| 35F (4) | 4 (100) | 1/1 (100) | 3/3 (100) | 2 | 1 | 2/3 (67) | 3/3 (100) | ||
| 35B (6) | 5 (83) | 3/4 (75) | 2/2 (100) | 2 | 0/2 | 2/2 (100) | |||
| 6C (4) | 2 (50) | 1/2 (50) | 1/2 (50) | 1 | 1 | 2/2 (100) | 2/2 (100) | ||
| 17F (4) | 4 (100) | 3/3 (100) | 1/1 (100) | 1 | 1/1(100) | 1/1 (100) | |||
| 22F(2), 29(2) | 2 (50) | 0/2 | 2/2 (100) | 1 | 2/2 (100) | 2/2(100) | |||
| 24F (2) | 1 (50) | 1/1 (100) | 0/1 | 1 | 0/1 | 0 | |||
| 15F (1) | 0 (0) | 0/1 (0) | 0/1 | 1 | 1/1 (100) | 1/1 (100) | |||
| 16(1) | 1 (100) | 0 | 1/1 (100) | 1 | 1/1 (100) | 1/1 (100) | |||
| 38 (1) | 1 (100) | 0 | 1/1 (100) | 1 | 0/1 | 1/ 1(100) | |||
| 8(2), 12F (1), 25A (1) 31 (1), 33F (1) | 5 (83.3) | 5/6 (83.3) | 0/0 | 0 | 0 | ||||
| Total | 67/101 (69.3) | 43/62 (69.3) | 36/57 (63.1) | 24 | 11 | 17 | 4 | 36/48 (75) | 46/48 (94.6) |
| NT (7) | 7 (100) | 3/3(100) | 4/4 (100) | 3 | 1 | 3/4 (75) | 4/4 (100) | ||
| Total | 127/190 (66.8%) | 64/95 (67.4%) | 64/97 (66%) | 46/65 (71%) | 18/65 (27.6%) | 26/32 (81.2%) | 6/32 (18.7%) | 71/94 (75.5%) | 89/94 (94.6%) |
PCV7: Serotypes included in the PCV7 vaccin
PCV13 additionnal serotypes: Additionnal serotypes added in the PCV13 vaccin
NT: non typable serotypes